About this Research Topic
One of the most common causes for referral to a pediatric endocrinologist globally is issues related to growth. Since the first patient was treated with growth hormone in 1965 questions remain regarding both the correct diagnosis and the treatment of such patients. While the identification and treatment options may be perfectly clear in certain instances such as in those patients with organic growth hormone deficiency and those with multiple pituitary hormone deficiency, for those patients who are evaluated controversy remains regarding both the diagnostic maneuvers as well as the therapeutic goals of growth disorders.
The relative abundance of recombinant growth hormone for treatment and the impending approval of long-acting growth hormone makes these issues particularly pertinent for discussion.
This Research Topic is dedicated to exploring some of the current controversies in light of most recent developments. Experts will present evidence-based data where available framed by expert opinions to help elucidate answers to some of these questions. We welcome original research, reviews, mini reviews, and perspective articles relating to the following subjects:
• Diagnosis of GH deficiency without GH stimulation tests
• Sex steroid priming of GH stimulation tests; Yes or No
• Initiation of hGH dose for licensed therapy: standard dose, IGF-1 titration or prediction factor finessing
• GH resistance is a component of idiopathic short stature: implications for hGH therapy
• Sex and racial disparities in hGH therapy and response
• hGH therapy in Noonan syndrome: is the FDA license appropriate
• Should pubertal development be manipulated for extra height gain?
• Will long-acting hGH therapy revolutionize growth management?
• Monitoring during growth hormone treatment what should be the standard
• Reassessment of GH secretion at completion of linear growth
• Growth hormone therapy for rare unlicensed severe short stature disorders
• Safety of pediatric hGH therapy: an overview and the need for long-term surveillance
The relative abundance of recombinant growth hormone for treatment and the impending approval of long-acting growth hormone makes these issues particularly pertinent for discussion.
This Research Topic is dedicated to exploring some of the current controversies in light of most recent developments. Experts will present evidence-based data where available framed by expert opinions to help elucidate answers to some of these questions. We welcome original research, reviews, mini reviews, and perspective articles relating to the following subjects:
• Diagnosis of GH deficiency without GH stimulation tests
• Sex steroid priming of GH stimulation tests; Yes or No
• Initiation of hGH dose for licensed therapy: standard dose, IGF-1 titration or prediction factor finessing
• GH resistance is a component of idiopathic short stature: implications for hGH therapy
• Sex and racial disparities in hGH therapy and response
• hGH therapy in Noonan syndrome: is the FDA license appropriate
• Should pubertal development be manipulated for extra height gain?
• Will long-acting hGH therapy revolutionize growth management?
• Monitoring during growth hormone treatment what should be the standard
• Reassessment of GH secretion at completion of linear growth
• Growth hormone therapy for rare unlicensed severe short stature disorders
• Safety of pediatric hGH therapy: an overview and the need for long-term surveillance
Keywords: Growth hormone treatment, growth hormone
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
